27.03
price down icon3.46%   -0.97
after-market アフターアワーズ: 27.20 0.17 +0.63%
loading
前日終値:
$28.00
開ける:
$28.04
24時間の取引高:
1.23M
Relative Volume:
0.56
時価総額:
$514.07M
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-18.51
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
-0.84%
1か月 パフォーマンス:
+10.42%
6か月 パフォーマンス:
+2,800%
1年 パフォーマンス:
+2,143%
1日の値動き範囲:
Value
$26.86
$29.70
1週間の範囲:
Value
$25.34
$29.70
52週間の値動き範囲:
Value
$0.432
$37.38

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1157)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
61
Name
Twitter
@nektarnews
Name
次回の収益日
2025-03-12
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

NKTR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NKTR
Nektar Therapeutics
27.03 521.68M 90.12M -276.06M -193.47M -1.46
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
Aug 18, 2025

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer - The Manila Times

Aug 18, 2025
pulisher
Aug 18, 2025

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

Can Nektar Therapeutics expand into new marketsWeekly Trade Report & AI Enhanced Trading Signals - thegnnews.com

Aug 18, 2025
pulisher
Aug 17, 2025

Institutions Profited After Nektar Therapeutics' (NASDAQ:NKTR) Market Cap Rose US$80m Last Week but Retail Investors Profited the Most - 富途牛牛

Aug 17, 2025
pulisher
Aug 17, 2025

Top 5 Articles of the Week: August 10-15 - Dermatology Times

Aug 17, 2025
pulisher
Aug 16, 2025

Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

Nektar Therapeutics Sees Relief Buying After Extended DropEarnings Overview Summary & Fast Exit Strategy with Risk Control - sundaytimes.kr

Aug 16, 2025
pulisher
Aug 15, 2025

Nektar gets FDA fast track status for alopecia areata drug - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Why Nektar Therapeutics Stock Popped 6% on Friday - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Nektar Therapeutics shares fall 1.61% premarket as cancer research funding faces uncertainty. - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment - MarketScreener

Aug 14, 2025
pulisher
Aug 13, 2025

Nektar Therapeutics’ Earnings Call Highlights Growth Potential - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

Quant Tools Rank Nektar Therapeutics as High Risk High Reward2025 Stock Rankings & AI Powered Market Entry Strategies - metal.it

Aug 13, 2025
pulisher
Aug 13, 2025

Institutional investors are Nektar Therapeutics' (NASDAQ:NKTR) biggest bettors and were rewarded after last week's US$59m market cap gain - simplywall.st

Aug 13, 2025
pulisher
Aug 12, 2025

Nektar Therapeutics Rebounds From Oversold Zone — Now WhatLong Term Wealth Forecast - beatles.ru

Aug 12, 2025
pulisher
Aug 12, 2025

Nektar Therapeutics (NASDAQ:NKTR) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 12, 2025
pulisher
Aug 11, 2025

How Nektar's Rezpegaldesleukin Could Redefine Treatment for Autoimmune Disorders - Dermatology Times

Aug 11, 2025
pulisher
Aug 11, 2025

Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail

Aug 11, 2025
pulisher
Aug 11, 2025

Nektar Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Aug 11, 2025
pulisher
Aug 09, 2025

Nektar Therapeutics Q2 2025 Earnings: Revenue Exceeds Estimates, EPS Loss Wider Than Expected, Cash and Investments Down to $175.9 Million - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Nektar Therapeutics Q2 Earnings: Revenue Down, Net Loss Up, but Cash Position Strong and FDA Fast Track Designation for Rezpegaldesleukin - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $98 to $120 - 富途牛牛

Aug 09, 2025
pulisher
Aug 09, 2025

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

Nektar Therapeutics 2025 Q2 Earnings Loss Narrows by 21.5% - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Nektar Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail

Aug 09, 2025
pulisher
Aug 08, 2025

Nektar Therapeutics (NKTR): A High-Risk, High-Reward Biotech Play in the Treg Space - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Nektar Therapeutics (NKTR) Stock Moves on Earnings and Fast Trac - GuruFocus

Aug 08, 2025
pulisher
Aug 08, 2025

Jonathan Zalevsky, PhD, on Rezpegaldesleukin’s Biologic Approach to Alopecia Areata - Dermatology Times

Aug 08, 2025
pulisher
Aug 08, 2025

Nektar Therapeutics: Operational Efficiency Gains Amid Revenue Decline—A Path to Profitability or a Temporary Reprieve? - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

William Blair Maintains Nektar Therapeutics(NKTR.US) With Hold Rating - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

Transcript : Nektar Therapeutics, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss By Investing.com - Investing.com Australia

Aug 08, 2025
pulisher
Aug 08, 2025

Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss - Investing.com

Aug 08, 2025
pulisher
Aug 08, 2025

Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada

Aug 08, 2025
pulisher
Aug 08, 2025

Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Highlights: Str - GuruFocus

Aug 08, 2025
pulisher
Aug 08, 2025

Nektar (NKTR) Q2 Revenue Falls 52% - The Globe and Mail

Aug 08, 2025

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Nektar Therapeutics (NKTR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Wilson Mark Andrew
Chief Legal Officer
Aug 19 '25
Sale
26.59
676
17,975
20,312
ROBIN HOWARD W
President & CEO
Aug 19 '25
Sale
26.59
1,573
41,826
69,340
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
大文字化:     |  ボリューム (24 時間):